For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ Nesfatin-1
Illustration for Nesfatin-1

THE PEPSRADAR ENCYCLOPEDIA

Nesfatin-1

Central feeding regulation

Research topics · Sources checked 2026-10-04

Read the studies ↓

Nesfatin-1 · KEY FACTS

Content updated · how dates work

Saved peptides

What is Nesfatin-1?

Nesfatin-1 is a NUCB2-derived peptide investigated in feeding regulation. Its foundational evidence involved central administration and signaling experiments in rats.

Biological role or research focus

Central feeding regulation.

Brain-administered animal results cannot establish effectiveness or exposure after peripheral administration in humans.

Role reference: Identification of nesfatin-1 as a satiety molecule in the hypothalamus. · 2006 ↗

Names you may encounter

NUCB2-derived nesfatin-1

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
NUCB2-derived peptide fragment
Research focus
Central feeding regulation
Featured evidence
Animal study
Source check
October 4, 2026

Source: Identification of nesfatin-1 as a satiety molecule in the hypothalamus. · 2006 ↗

Quick answers

Is Nesfatin-1 FDA approved?
No. No FDA-approved drug contains Nesfatin-1. Source ↗
Is Nesfatin-1 safe?
Unapproved appetite-related peptide with no published human safety studies; lab findings link it to blood-vessel calcification and some cancers. Human safety data: none. The Risks & interactions section below lists what is known. Read the risks ↓
Is Nesfatin-1 banned in sport?
Very likely. The 2026 World Anti-Doping Agency (WADA) Prohibited List does not name it, but it appears to fall under a banned class (S0 Non-approved substances). Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

1 Animal / mixed laboratory research
StudyTypePopulation / model
Discovery of nesfatin-related satiety signaling (2006)Animal studyRats used in central feeding-regulation experiments.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Animal study · 2006

Discovery of nesfatin-related satiety signaling

What did this publication test, and what did it find?

Population / model
Rats used in central feeding-regulation experiments.
Study design
Identification of hypothalamic NUCB2-related signaling followed by acute and repeated central administration experiments.
Main finding
Central administration reduced food intake, and repeated administration changed weight-related measures in the experimental setting.
Limits & context
Brain-administered animal results cannot establish effectiveness or exposure after peripheral administration in humans.

Source: Identification of nesfatin-1 as a satiety molecule in the hypothalamus. · 2006 ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

4 registered studies name Nesfatin-1 as an intervention; 0 are recruiting or under way, 0 have not started recruiting yet, 2 completed and 2 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.

StudyStatusPhaseStartPeople
Serum Nesfatin-1 and Human Cartilage Glycoprotein-39 Levels in Knee Osteoarthritis
NCT06254976 · Kayseri City Hospital
CompletedNot applicable2022-06-0130
Nesfatin-1 Level in Patients With Type 2 Diabetes, Insulin Resistance and Obesity
NCT04298515 · Istanbul Medeniyet University
Status unknownNot applicable2020-03-02180
Role of Nesfatin-1 and Nicotinamide in Infertile Women With Polycystic Ovary Syndrome
NCT03870035 · Assiut University
Status unknown2019-05-0156
Cord Blood Nesfatin-1 and Irisin in the Intrauterine Growth Restricted Fetuses
NCT03808571 · Yuzuncu Yil University
Completed2018-01-0166

A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination.

Further reading · 4 additional publication links

Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.

Nesfatin-1 enhances vascular smooth muscle calcification through facilitating BMP-2 osteogenic signaling. ↗
Cell communication and signaling : CCS · 2024 Oct 11 · Journal Article, Research Support, Non-U.S. Gov't
Read available full text ↗

Nucleobindin-2/Nesfatin-1-A New Cancer Related Molecule? ↗
International journal of molecular sciences · 2021 Aug 2 · Journal Article, Review
Read available full text ↗

New developments on NUCB2/nesfatin-1. ↗
Current pharmaceutical design · 2013 · Editorial, Introductory Journal Article

Multi-functional peptide hormone NUCB2/nesfatin-1. ↗
Endocrine · 2013 Oct · Journal Article, Review

Repeat this PubMed search ↗
Search additional PubMed records ↗

Risks & interactions

Unapproved appetite-related peptide with no published human safety studies; lab findings link it to blood-vessel calcification and some cancers.

Human safety data: None

No published studies of giving nesfatin-1 to people were found. Evidence comes from rat brain experiments and from measuring the body's own levels, which cannot show what an administered product would do.

Unassessed: no human safety data

Warning signs in animal or lab studies: Cancer, now or in the past

It isn't approved, so there is no official list of who should avoid it, and no human safety studies have been published. These tags come only from the studies and warnings summarized below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.

Who should not use it

There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.

Harms seen in animal or lab studies

  • In cell and animal experiments, nesfatin-1 promoted calcification of blood-vessel muscle cells
  • High nesfatin-1 (NUCB2) levels have been linked to cancer cell growth and spread in several tumor types

Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: Identification of nesfatin-1 as a satiety molecule (Nature, 2006) ↗ · Nesfatin-1 enhances vascular smooth muscle calcification (2024) ↗ · Nucleobindin-2/nesfatin-1: a new cancer-related molecule? (review) ↗

Safety & what remains unknown

The central experimental route and animal follow-up cannot define safe human use.

Source: Identification of nesfatin-1 as a satiety molecule in the hypothalamus. · 2006 ↗

Evidence boundaries

Brain-administered animal results cannot establish effectiveness or exposure after peripheral administration in humans.

Source: Identification of nesfatin-1 as a satiety molecule in the hypothalamus. · 2006 ↗

Regulatory status

U.S. FDA approval
Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source
FDA compounding (503A bulk list)
Not on FDA’s compounding lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (updated April 22, 2026). source
World Anti-Doping Agency (2026)
Likely prohibited under a class rule · S0 Non-approved substances
Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Research context & identity

This page covers animal neuroendocrine research. It does not establish a clinically effective human weight-loss product.

Source: Identification of nesfatin-1 as a satiety molecule in the hypothalamus. · 2006 ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.

No verified matching catalog listing yet

We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.

Biology & proposed mechanism

The study connected the fragment to hypothalamic feeding circuits and melanocortin-associated responses. Direct administration into the brain is not equivalent to other routes.

Source: Identification of nesfatin-1 as a satiety molecule in the hypothalamus. · 2006 ↗

Questions worth asking

  • Can the rat feeding result be transferred to a research vial?
  • What material, population, and route were actually studied?
  • Brain-administered animal results cannot establish effectiveness or exposure after peripheral administration in humans.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Frequently asked questions

Can the rat feeding result be transferred to a research vial?

No. Identity, route, exposure, and human outcomes require separate evidence.

Source: Identification of nesfatin-1 as a satiety molecule in the hypothalamus. · 2006 ↗

Does the publication verify a supplier’s product?

No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.

Source: Identification of nesfatin-1 as a satiety molecule in the hypothalamus. · 2006 ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections